What is Yutopar?
Yutopar (ritodrine) is a tocolytic agent, indicated for the treatment of uncomplicated premature labor.
Yutopar is contra-indicated in patients with pregnancy induced hypertension, bleeding during pregnancy, intrauterine fetal death, heart disease, miscarriage and cord compression.
Yutopar falls in pregnancy category B. Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
PO- 10 mg 30-60 mins before termination of IV infusion, repeat 2 hourly for 24 hour, then 10-20 mg 4-6 hourly. Max: 120 mg/day.
Infuse at 0.05 mg/min. Increase gradually till patient responds. Usual: 0.15-0.35 mg/min.
IM 10- mg 3-8 hourly. Maintain for 12-48 hour after contractions have stopped.
- Caution should be exercised in patients with history of heart disease, concurrent steroids, over active thyroid, heart attack, high blood pressure, sugar, asthma and breastfeeding
- Monitor plasma glucose and potassium level
- Monitor maternal pulse count throughout infusion; adjust rate to avoid maternal heartbeat exceeding 140 beats/min
Yutopar (ritodrine) may have the following side effects;
Fast heart rate, palpitation, headache, nervousness, anxiety, nausea and vomiting.
Potentially Fatal Lung swelling and severe allergic reactions have also been reported with the usage of Yutopar.
It is recommended o monitor the hydration status of the patient in order to avoid the possible risk of lung swelling. Stop taking Yutopar if there are signs of lung swelling.